Prevention and control of meningococcal disease: updates from the Global Meningococcal Initiative in Eastern Europe.

Clicks: 432
ID: 64704
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 16 articles by views in the journal of infection

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.
Reference Key
bai2019preventionthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bai, Xilian;Borrow, Ray;Bukovski, Suzana;Caugant, Dominique A;Culic, Davor;Delic, Snezana;Dinleyici, Ener Cagri;Eloshvili, Medeia;Erdősi, Tímea;Galajeva, Jelena;Křížová, Pavla;Lucidarme, Jay;Mironov, Konstantin;Nurmatov, Zuridin;Pana, Marina;Rahimov, Erkin;Savrasova, Larisa;Skoczyńska, Anna;Smith, Vinny;Taha, Muhamed-Kheir;Titov, Leonid;Vázquez, Julio;Yeraliyeva, Lyazzat;
Journal the journal of infection
Year 2019
DOI
S0163-4453(19)30332-9
URL
Keywords
antibiotic resistance refugees surveillance vaccination eastern europe bacterial meningitis carriage conjugate vaccine emerging strains high-risk groups immunization program meningococcal disease neisseria meningitidis polysaccharide vaccine serogroup

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.